Please login to the form below
Measures for measures
Why pharma’s marketing metrics must close the loop
The March issue of PME tackles the complexities of choosing the right digital marketing KPIs.
Assessing marketing effectiveness in the digital world has fast become one of the biggest challenges facing the pharmaceutical industry. Distilling the vast amount of data available to marketeers often results in a dizzying array of KPIs, leaving many with information overload.
Dennis O’Brien, Lucid CEO, believes that the traditional method, in which digital strategy feeds into digital KPIs, needs reversing. “It’s the wrong way round. Digital KPIs should instead be driven by – and feed into – the marketing strategy.” Digital tools provide an amazing opportunity to reach, connect and understand customers in a way that was not previously possible. This enables one to ‘close the loop’, understand what isn’t working, and then ask, how can we fix it?
Nigel Horn, Managing Director of digital and creative design company Bluedog, a Lucid Group company, also believes that the key is to start and end with the marketing objectives: it’s a circular journey. “The closed-loop approach allows us to measure not only whether we’re touching our target customers, but also, crucially, whether we’re influencing them in the ways we need to change behaviour.” comments Nigel. Bluedog capture this principle perfectly in The Dog TestTM, whereby tactics and metrics are evaluated to see if they meet marketing and brand objectives.
To find out more, read the full article here https://bit.ly/2O6XNBJ
Company Details
Lucid Group Communications Limited
Address:
First Floor, Jubilee House
Third Avenue
Globe Park
Marlow
Bucks
SL7 1EY
UK
Latest content on this profile
- My Lucid journey from PMW to Head of Medical
- Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced and demanding industry, but one which offers enviable flexibility, variety and intellectual challenge. Leading agency Lucid Group prides itself on the many growth and development opportunities it offers its people. In this article, Katherine Duxbury, Lucid’s Head of Medical, reflects upon her own bespoke working journey over the past 12 years and explains how creativity, collaboration and a passion for science have led to a rewarding, stimulating and self-curated career.
Lucid Group Communications Limited
- Listen, learn and lift off
Lucid Group Communications Limited
- Launch excellence
Lucid Group Communications Limited
- Meet The Lucid Group Talent Team
- Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your career to the next level with us, you can be assured that you'll have a whole group of people here cheering you on.So, if you’re feeling stuck or unfulfilled in your current role and looking for a company that will provide the personal and career development you need, please check out our open roles here: https://bit.ly/3jhlhUNOr contact one of our talent acquisition managers for a chat:Ellen Field Assoc CIPDElaine DowneyJon TurnerDaniel Newbury
Lucid Group Communications Limited
- Extraordinary lives: advancing change in rare diseases (Part 2)
Lucid Group Communications Limited
- Extraordinary lives: advancing change in rare diseases (Part 2)
- In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so important?Because 300 million people worldwide are living with a rare disease. This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world's third-largest country (USA).While we have come a long way since the inception of Rare Disease Day, there's still plenty of work to do.Part 2 of this series focuses on important topics including the role of technology and the opportunities it presents for the rare disease community. The panel also hold captivating insights on how the pandemic has impacted the use of related digital technologies, the role of gene therapy, the major challenges and successes for pharma companies in supporting the rare disease community over the last 13 years, and much, much more.If you’d like to know more about the work we do in rare diseases or would like advice on any healthcare communication challenges please get in touch with Clare Reynolds on LinkedIn or by email: clare.reynolds@wearelucidgroup.comAbout Lucid GroupFounded in 2007, Lucid Group is a global multi-capability healthcare consultancy with core expertise in medical strategy, healthcare communications, creative and brand strategy, motion, digital and technology, behaviour change, metrics, and data analytics. We partner with the pharma and biotech industry, delivering life-transforming value with connected capabilities to create pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. Transforming lives. Always.
Lucid Group Communications Limited
